Ningbo Lihua Pharmaceutical

Ningbo Lihua Pharmaceutical is a prominent Chinese pharmaceutical manufacturer and a key subsidiary of Zhejiang Hisun Pharmaceutical. Founded in 1994 and headquartered in Ningbo, the company specializes in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms, particularly those involving complex fermentation and chemical synthesis. Its product portfolio is heavily focused on immunosuppressants, including mycophenolate mofetil, tacrolimus, and sirolimus, alongside treatments for cardiovascular and infectious diseases. The company's facilities are GMP-certified and have successfully passed audits from major international regulatory bodies, including the US FDA. As a core manufacturing site within the Hisun Group, Ningbo Lihua plays a vital role in supplying high-quality generic medications to both domestic and global markets.